Compare HEQ & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HEQ | OVID |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.9M | 116.8M |
| IPO Year | N/A | 2017 |
| Metric | HEQ | OVID |
|---|---|---|
| Price | $10.78 | $1.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 43.1K | ★ 1.9M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 9.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,610,000.00 |
| Revenue This Year | N/A | $1,077.56 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 945.89 |
| 52 Week Low | $9.08 | $0.24 |
| 52 Week High | $11.84 | $2.01 |
| Indicator | HEQ | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 60.01 |
| Support Level | $10.70 | $1.26 |
| Resistance Level | $10.82 | $1.64 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 25.01 | 83.87 |
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.